X-ray volumetric imaging in image-guided radiotherapy: the new standard in on-treatment imaging.
Authors
McBain, Catherine AHenry, Ann M
Sykes, Jonathan R
Amer, Ali M
Marchant, Thomas E
Moore, Christopher J
Davies, Julie
Stratford, Julia
McCarthy, Claire
Porritt, Bridget
Williams, Peter C
Khoo, Vincent S
Price, Patricia M
Affiliation
Academic Department of Radiation Oncology, Christie Hospital NHS Trust, Manchester, England, United Kingdom. catherine.mcbain@christie-tr.nwest.nhs.ukIssue Date
2006-02-01
Metadata
Show full item recordAbstract
PURPOSE: X-ray volumetric imaging (XVI) for the first time allows for the on-treatment acquisition of three-dimensional (3D) kV cone beam computed tomography (CT) images. Clinical imaging using the Synergy System (Elekta, Crawley, UK) commenced in July 2003. This study evaluated image quality and dose delivered and assessed clinical utility for treatment verification at a range of anatomic sites. METHODS AND MATERIALS: Single XVIs were acquired from 30 patients undergoing radiotherapy for tumors at 10 different anatomic sites. Patients were imaged in their setup position. Radiation doses received were measured using TLDs on the skin surface. The utility of XVI in verifying target volume coverage was qualitatively assessed by experienced clinicians. RESULTS: X-ray volumetric imaging acquisition was completed in the treatment position at all anatomic sites. At sites where a full gantry rotation was not possible, XVIs were reconstructed from projection images acquired from partial rotations. Soft-tissue definition of organ boundaries allowed direct assessment of 3D target volume coverage at all sites. Individual image quality depended on both imaging parameters and patient characteristics. Radiation dose ranged from 0.003 Gy in the head to 0.03 Gy in the pelvis. CONCLUSIONS: On-treatment XVI provided 3D verification images with soft-tissue definition at all anatomic sites at acceptably low radiation doses. This technology sets a new standard in treatment verification and will facilitate novel adaptive radiotherapy techniques.Citation
X-ray volumetric imaging in image-guided radiotherapy: the new standard in on-treatment imaging. 2006, 64 (2):625-34 Int. J. Radiat. Oncol. Biol. Phys.Journal
International Journal of Radiation Oncology, Biology, PhysicsDOI
10.1016/j.ijrobp.2005.09.018PubMed ID
16343802Type
ArticleLanguage
enISSN
0360-3016ae974a485f413a2113503eed53cd6c53
10.1016/j.ijrobp.2005.09.018
Scopus Count
Collections
Related articles
- Effects of megavoltage computed tomographic scan methodology on setup verification and adaptive dose calculation in helical TomoTherapy.
- Authors: Zhu J, Bai T, Gu J, Sun Z, Wei Y, Li B, Yin Y
- Issue date: 2018 Apr 27
- Interfractional variations in patient setup and anatomic change assessed by daily computed tomography.
- Authors: Li XA, Qi XS, Pitterle M, Kalakota K, Mueller K, Erickson BA, Wang D, Schultz CJ, Firat SY, Wilson JF
- Issue date: 2007 Jun 1
- A Technique to Rapidly Generate Synthetic Computed Tomography for Magnetic Resonance Imaging-Guided Online Adaptive Replanning: An Exploratory Study.
- Authors: Ahunbay EE, Thapa R, Chen X, Paulson E, Li XA
- Issue date: 2019 Apr 1
- A feasibility study for image guided radiotherapy using low dose, high speed, cone beam X-ray volumetric imaging.
- Authors: Sykes JR, Amer A, Czajka J, Moore CJ
- Issue date: 2005 Oct
- Dose calculation and treatment plan optimization including imaging dose from kilovoltage cone beam computed tomography.
- Authors: Alaei P, Spezi E, Reynolds M
- Issue date: 2014 Jun
Related items
Showing items related by title, author, creator and subject.
-
Treatment for non small cell lung cancer, small cell lung cancer and pleural mesothelioma within the EORTC Lung Cancer Group: past, present and future.O'Brien, M; van Meerbeeck, J; Surmont, V; Faivre-Finn, Corinne (2012)
-
Ovarian cancer among 8,005 women from a breast cancer family history clinic: no increased risk of invasive ovarian cancer in families testing negative for BRCA1 and BRCA2.Ingham, S; Warwick, J; Buchan, I; Sahin, S; O'Hara, Catherine; Moran, Anthony; Howell, Anthony; Evans, D; Centre for Health Informatics, Institute of Population Health, The University of Manchester, Manchester, UK. (2013-06)Mutations in BRCA1/2 genes confer ovarian, alongside breast, cancer risk. We examined the risk of developing ovarian cancer in BRCA1/2-positive families and if this risk is extended to BRCA negative families.
-
AZD8186 study 1: phase I study to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary anti-tumour activity of AZD8186 in patients with advanced castration-resistant prostate cancer (CRPC), squamous non-small cell lung cancer, triple negative breast cancer and with PTEN-deficient/mutated or PIK3CB mutated/amplified malignancies, as monotherapy and in combination with vistusertib (AZD2014) or abiraterone acetate.Lillian, S; De Bono, J; Higano, C; Shapiro, G; Brugger, W; Mitchell, P; Colebrook, S; Klinowska, T; Barry, S; Dean, Emma J; et al. (2016-12)